Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2625 total matches.
In Brief: Dapagliflozin (Farxiga) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021 (Issue 1629)
in eGFR ≥50% 5.2% 9.3%
End-stage renal disease 5.1% 7.5%
CV death 3.0% 3.7%
Renal death ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
dapagliflozin (Farxiga – AstraZeneca) has been
approved by the FDA for treatment of adults with
chronic kidney disease (CKD) at risk of progression
(not defined in the label). Dapagliflozin is the first
SGLT2 inhibitor to be approved in the US for treatment
of CKD.
In Brief: FDA Azithromycin Warning
The Medical Letter on Drugs and Therapeutics • Apr 01, 2013 (Issue 1413)
The Medical Letter®
On Drugs and Therapeutics
Volume 55 (Issue 1413)
April 1, 2013
Published ...
The FDA has announced that it is requiring changes in the labeling of the macrolide antibiotic azithromycin (Zithromax, Zmax) to warn about the risk of QT prolongation and cardiac arrhythmias.1 The new warnings are based on a retrospective study in The New England Journal of Medicine (reviewed previously in The Medical Letter2), which found that among patients who received 347,795 prescriptions for azithromycin, there were 29 cardiovascular deaths, a significantly higher rate than the 42 that occurred among patients who received 1,348,672 prescriptions for amoxicillin (which does not prolong...
COVID-19 Update: Full Approval for Novavax COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025 (Issue 1733)
Use Authorization
(EUA) for use in persons ≥12 years old.1 Nuvaxovid is
the first protein-based ...
Nuvaxovid, the adjuvanted protein subunit COVID-19
vaccine marketed by Novavax, has received full
approval from the FDA to prevent COVID-19 caused
by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) in all adults ≥65 years old and in adults
12-64 years old who have at least one underlying
condition that puts them at high risk for severe
outcomes from COVID-19. The vaccine was previously
available under an FDA Emergency Use Authorization
(EUA) for use in persons ≥12 years old.1 Nuvaxovid is
the first protein-based COVID-19 vaccine to receive
full approval from the...
Med Lett Drugs Ther. 2025 Jul 21;67(1733):118-9 doi:10.58347/tml.2025.1733f | Show Introduction Hide Introduction
Insulins for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
patients, the target A1C is ...
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
insomnia
...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Desogestrel - A New Progestin for Oral Contraception
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993 (Issue 902)
CONTRACEPTIVES
1
Estrogen (µg) µg per mg per
Drug (ethinyl estradiol) month Progestin (mg)
2
month Cost
3 ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
A New Testosterone Gel (Fortesta) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 ...
The FDA has approved Fortesta (Endo), a topical gel,
for testosterone replacement therapy in adult males
with hypogonadism. It is classified as a Schedule III
controlled substance. Table 1 lists some available
testosterone products, including 2 other gels.
Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
significantly less often in patients who received the
antibodies than in those who received placebo (1.5%
vs ...
The investigational monoclonal antibodies casirivimab
and imdevimab (REGEN-COV – Regeneron) have
been available in the US under an Emergency Use
Authorization (EUA) since late 2020 for use together
to treat mild to moderate COVID-19 in persons ≥12
years old who weigh ≥40 kg and are at high risk of
progression to severe disease or hospitalization. The
FDA has now expanded this EUA to allow use of the
antibodies together for post-exposure prophylaxis
of COVID-19 in such persons, if they are not fully
vaccinated against COVID-19 or are unlikely to have
an adequate immune response...
Tafenoquine (Arakoda; Krintafel) for Malaria
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019 (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh
Krintafel: krin tah fell
Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting
analog of primaquine, has been approved by
the FDA in 2 different strengths. Arakoda (100-mg
tablets; Sixty Degrees) is indicated for the prophylaxis
of malaria in adults. Krintafel (150-mg tablets; GSK) is
indicated for the prevention of relapse (radical cure)
of Plasmodium vivax malaria in patients ≥16 years old
undergoing treatment for acute P. vivax infection.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
.............................................................................. p 1
CHA2DS2-VASc Scoring ............................................................. p 2
Oral ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
